This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Medpace (MEDP) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 39.46% and 8.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Medpace (MEDP) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Medpace (MEDP) closed at $147.53 in the latest trading session, marking a -0.05% move from the prior day.
Tandem Diabetes (TNDM) Q2 Earnings Miss, Sales View Cut
by Zacks Equity Research
Factoring the pandemic and competitive pressure as well as the evolving economic environment, including inflation and the threat of recession, Tandem Diabetes (TNDM) cuts its full-year guidance.
3 Reasons Growth Investors Will Love Medpace (MEDP)
by Zacks Equity Research
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
CVS Health (CVS) Q2 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
CVS Health (CVS) posts better-than-expected results in Q2, with robust performances across all operating segments driving the top line.
Exact Sciences (EXAS) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Exact Sciences (EXAS) posts better-than-expected earnings and revenues in Q2 with robust performances across the Screening and Precision Oncology segments.
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut
by Zacks Equity Research
Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.
STERIS (STE) Q1 Earnings Match Estimates, EPS View Down
by Zacks Equity Research
STERIS' (STE) revenues at AST improve driven by increased demand from medical device and biopharma customers.
Henry Schein (HSIC) Q2 Earnings Top Estimates, '22 EPS View Up
by Zacks Equity Research
Henry Schein (HSIC) reports better-than-expected Q2 earnings with impressive sales growth across the Medical and Technology and Value-added Services segments.
Teleflex's (TFX) Q2 Earnings Top Estimates, 2022 View Down
by Zacks Equity Research
For UroLift, Teleflex (TFX) witnesses revenue declines in all sites of service, including hospital, ASC and physician's office.
Chemed (CHE) Q2 Earnings Surpass Estimates, Margins Grow
by Zacks Equity Research
Chemed (CHE) reports better-than-expected earnings in the second quarter, with a robust performance by the Roto-Rooter segment driving the top line.
Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up
by Zacks Equity Research
Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.
Amedisys (AMED) Q2 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Lower utilization of home health benefit, primarily driven by lesser total discharges to post-acute settings, hampers Amedisys' (AMED) Q2 revenues.
Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Gross Margin Up
by Zacks Equity Research
Overall demand for Bio-Rad's (BIO) Life Science and Clinical Diagnostics continues to be strong on localized surges of COVID-19.
LabCorp (LH) Q2 Earnings Top Estimates, Raises '22 EPS View
by Zacks Equity Research
LabCorp (LH) posts better-than-expected earnings in the second quarter and demonstrates continued strength in the organic Base Business.
Hologic (HOLX) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Hologic (HOLX) reports better-than-expected results in the fiscal third quarter with robust sales performance in the GYN Surgical business.
QIAGEN (QGEN) Q2 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
QIAGEN (QGEN) posts better-than-expected results for the second quarter and raises its sales and earnings outlook for 2022 amid the uncertain macroeconomic environment.
Thermo Fisher (TMO) Q2 Earnings Top Estimates, Margins Down
by Zacks Equity Research
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Specialty Diagnostics segment revenues is disappointing.
West Pharmaceutical (WST) Q2 Earnings Beat, FY22 View Cut
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter earnings reflect strength in the Proprietary Products segment.
Merit Medical (MMSI) Q2 Earnings Beat, FY22 View Revised
by Zacks Equity Research
Merit Medical (MMSI), in the second quarter, benefits from revenue growth in both its segments and from all product categories within its Cardiovascular unit.
Ecolab's (ECL) Q2 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across all of its segments drives its Q2 sales, despite business challenges.
Medpace (MEDP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Medpace (MEDP) delivered earnings and revenue surprises of 8.96% and 1.29%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in its Medication Delivery and BioPharma Solutions businesses. Hillrom's products are likely to have boosted sales
The Zacks Analyst Blog Highlights EQT, Medpace Holdings, Crane Holdings, Zions Bancorporation and Hess
by Zacks Equity Research
EQT, Medpace Holdings, Crane Holdings, Zions Bancorporation and Hess are included in this Analyst Blog.
Should You Buy Medpace (MEDP) Ahead of Earnings?
by Zacks Equity Research
Medpace (MEDP) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.